Global Commercial Footprint -- Over 175 active sites are currently using ClearPoint technology, with expectations to surpass ...

SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain ...

Reported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth ...

“Gross margin for the first quarter of 2026 was 64%,” while cash and cash equivalents were “$35.6 million as compared to $45.9 million at December 31, 2025,” with the reduction “primarily due to the ...

ClearPoint Neuro, Inc. (CLPT) is scheduled to announce Q1 earnings results on Wednesday, May 13th, after market close. The consensus EPS estimate is -$0.27, and the consensus revenue estimate is ...

CEO Joseph Burnett stated that ClearPoint Neuro ended 2025 on its strongest financial quarter of the year, highlighting "a newly acquired and commercialized neurocritical care product line and genuine ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

William Wood, an analyst from B.Riley Financial, reiterated the Buy rating on ClearPoint Neuro (CLPT – Research Report). The associated price target is $10.00. William Wood’s rating is based on ...

ClearPoint Health (“ClearPoint”) is a medical stop-loss captive platform for small and mid-sized employers. ClearPoint’s platform empowers employers and benefit advisors to transition employee health ...

Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ...